Composition comprising an IgE antibody
AssigneeKings's College London
InventorsJames Spicer, Sophia Karagiannis, Mariangela Figini, Hannah Gould
Life of this patent
Estimating the term…
Abstract
In one aspect, the present invention relates to a pharmaceutical unit dosage composition comprising an antibody of isotype immunoglobulin E (IgE), wherein the composition comprises less than 50 mg of the IgE antibody. The pharmaceutical unit dosage compositions may be administered to a mammalian subject and find use in treating cancer, in particular, human ovarian cancers.
Claims21
A pharmaceutical unit dosage composition comprising 500 μg to 50 mg of a monoclonal antibody of isotype immunoglobulin E (IgE), wherein the monoclonal antibody is a MOv18 IgE monoclonal antibody comprising the light chain variable domain amino acid sequence as defined in SEQ ID NO:3 and the heavy chain variable domain amino acid sequence as defined in SEQ ID NO:
- 4.
A method for treating and/or delaying progression of a folate receptor-positive cancer in a human subject in need thereof, said method comprising administering a pharmaceutical unit dosage composition comprising 500 μg to 50 mg of a monoclonal antibody of isotype immunoglobulin E (IgE), wherein the monoclonal antibody is a MOv18 IgE monoclonal antibody comprising the light chain variable domain amino acid sequence as defined in SEQ ID NO:3 and the heavy chain variable domain amino acid sequence as defined in SEQ ID NO:4.
Dependencies are inferred from the claim text.